Crescent Biopharma (CBIO) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Bright Minds Biosciences (DRUG) over the past year, gaining 21.5% versus a loss of 12.0%. Over five years, DRUG leads with a +45.5% price change compared with -92.9% for CBIO. Crescent Biopharma is the larger company by market cap ($553.9 million vs $533.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | DRUG |
|---|---|---|
| Share price | $14.91 | $54.05 |
| Market cap | $553.86M | $533.15M |
| 1-day change | +5.59% | +3.94% |
| YTD return | +25.72% | -30.74% |
| 1-year return | +21.52% | -11.99% |
| 5-year return | -92.87% | +45.49% |
| EPS (TTM) | $-7.63 | $-2.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $123.75 |
| 52-week low | $8.72 | $47.23 |
| Distance from 52-week high | -45.60% | -56.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.27% | +181.17% |
| Average volume | 400.72K | 156.28K |
| Shares outstanding | 37.14M | 9.86M |
| Employees | 69 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed DRUG by 33.5 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
CBIO vs DRUG FAQ
Which is bigger, Crescent Biopharma or Bright Minds Biosciences?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $553.86M compared with $533.15M for Bright Minds Biosciences (DRUG).
Which stock has performed better over the past year, CBIO or DRUG?
CBIO returned +21.52% over the past 12 months, compared with -11.99% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.